IDH1 and glioma: A trend observed indicated that tumors associated with poorer outcomes, such as recurrent tumors and Isocitrate Dehydrogenase (IDH) wildtype, displayed higher viability on-chip than tumors linked with improved outcomes, such as low-grade gliomas, IDH mutants, and primary tumors [233].